148 related articles for article (PubMed ID: 34160805)
1. In Vitro Silencing of lncRNAs Using LNA GapmeRs.
Taiana E; Favasuli V; Ronchetti D; Morelli E; Tassone P; Viglietto G; Munshi NC; Neri A; Amodio N
Methods Mol Biol; 2021; 2348():157-166. PubMed ID: 34160805
[TBL] [Abstract][Full Text] [Related]
2. Knockdown of Nuclear lncRNAs by Locked Nucleic Acid (LNA) Gapmers in Nephron Progenitor Cells.
Nishikawa M; Yanagawa N
Methods Mol Biol; 2020; 2161():29-36. PubMed ID: 32681503
[TBL] [Abstract][Full Text] [Related]
3. Tips for Successful lncRNA Knockdown Using Gapmers.
Lennox KA; Behlke MA
Methods Mol Biol; 2020; 2176():121-140. PubMed ID: 32865787
[TBL] [Abstract][Full Text] [Related]
4. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
5. Knockdown of Long Noncoding RNA Plasmacytoma Variant Translocation 1 with Antisense Locked Nucleic Acid GapmeRs Exerts Tumor-Suppressive Functions in Human Acute Erythroleukemia Cells Through Downregulation of
Salehi M; Sharifi M; Bagheri M
Cancer Biother Radiopharm; 2019 Aug; 34(6):371-379. PubMed ID: 30141968
[No Abstract] [Full Text] [Related]
6. Non-Coding RNA Silencing in Mammalian Cells by Antisense LNA GapmeRs Transfection.
Alfeghaly C; Aigueperse C; Maenner S; Behm-Ansmant I
Methods Mol Biol; 2021; 2300():31-37. PubMed ID: 33792869
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro.
Iwashita S; Shoji T; Koizumi M
Methods Mol Biol; 2020; 2176():155-161. PubMed ID: 32865789
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of Nuclear-Located Enhancer RNAs and Long ncRNAs Using Locked Nucleic Acid GapmeRs.
Roux BT; Lindsay MA; Heward JA
Methods Mol Biol; 2017; 1468():11-8. PubMed ID: 27662866
[TBL] [Abstract][Full Text] [Related]
9. An Investigation into the Potential of Targeting
Goddard LR; Mardle CE; Gneid H; Ball CG; Gowers DM; Atkins HS; Butt LE; Watts JK; Vincent HA; Callaghan AJ
Molecules; 2021 Jun; 26(11):. PubMed ID: 34200016
[TBL] [Abstract][Full Text] [Related]
10. Antisense locked nucleic acids efficiently suppress BCR/ABL and induce cell growth decline and apoptosis in leukemic cells.
Rapozzi V; Cogoi S; Xodo LE
Mol Cancer Ther; 2006 Jul; 5(7):1683-92. PubMed ID: 16891454
[TBL] [Abstract][Full Text] [Related]
11. Filling the gap in LNA antisense oligo gapmers: the effects of unlocked nucleic acid (UNA) and 4'-C-hydroxymethyl-DNA modifications on RNase H recruitment and efficacy of an LNA gapmer.
Fluiter K; Mook OR; Vreijling J; Langkjaer N; Højland T; Wengel J; Baas F
Mol Biosyst; 2009 Aug; 5(8):838-43. PubMed ID: 19603119
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2'-O-methyl RNA, phosphorothioates and small interfering RNA.
Grünweller A; Wyszko E; Bieber B; Jahnel R; Erdmann VA; Kurreck J
Nucleic Acids Res; 2003 Jun; 31(12):3185-93. PubMed ID: 12799446
[TBL] [Abstract][Full Text] [Related]
13. Ribonuclease H1-dependent hepatotoxicity caused by locked nucleic acid-modified gapmer antisense oligonucleotides.
Kasuya T; Hori S; Watanabe A; Nakajima M; Gahara Y; Rokushima M; Yanagimoto T; Kugimiya A
Sci Rep; 2016 Jul; 6():30377. PubMed ID: 27461380
[TBL] [Abstract][Full Text] [Related]
14. Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides.
Lennox KA; Behlke MA
Nucleic Acids Res; 2016 Jan; 44(2):863-77. PubMed ID: 26578588
[TBL] [Abstract][Full Text] [Related]
15. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents.
Stein CA; Hansen JB; Lai J; Wu S; Voskresenskiy A; Høg A; Worm J; Hedtjärn M; Souleimanian N; Miller P; Soifer HS; Castanotto D; Benimetskaya L; Ørum H; Koch T
Nucleic Acids Res; 2010 Jan; 38(1):e3. PubMed ID: 19854938
[TBL] [Abstract][Full Text] [Related]
16. Methods Used to Make Lipid Nanoparticles to Deliver LNA Gapmers Against lncRNAs into Acute Myeloid Leukemia (AML) Blasts.
Kuo CT; Lee RJ; Garzon R
Methods Mol Biol; 2021; 2348():167-174. PubMed ID: 34160806
[TBL] [Abstract][Full Text] [Related]
17. Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity.
Cai Y; Makarova AM; Wengel J; Howard KA
J Gene Med; 2018 Jul; 20(7-8):e3025. PubMed ID: 29800498
[TBL] [Abstract][Full Text] [Related]
18. Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.
Amodio N; Stamato MA; Juli G; Morelli E; Fulciniti M; Manzoni M; Taiana E; Agnelli L; Cantafio MEG; Romeo E; Raimondi L; Caracciolo D; Zuccalà V; Rossi M; Neri A; Munshi NC; Tagliaferri P; Tassone P
Leukemia; 2018 Sep; 32(9):1948-1957. PubMed ID: 29487387
[TBL] [Abstract][Full Text] [Related]
19. Role of Computationally Evaluated Target Specificity in the Hepatotoxicity of Gapmer Antisense Oligonucleotides.
Kasuya T; Kugimiya A
Nucleic Acid Ther; 2018 Oct; 28(5):312-317. PubMed ID: 30095329
[TBL] [Abstract][Full Text] [Related]
20. In Vivo Administration of Therapeutic Antisense Oligonucleotides.
Statello L; Ali MM; Kanduri C
Methods Mol Biol; 2021; 2254():273-282. PubMed ID: 33326082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]